Omnix Medical

Omnix Medical is developing an arsenal of next-generation antibiotics to treat drug-resistant bacterial infections by mimicking the anti-bacterial mechanisms of insects, which use antimicrobial peptides to fight off infections.

Omnix’s proprietary platform technology aims to tilt the odds in the battle against resistant bacteria to improve the lives of millions worldwide, save billions of dollars and prevent millions of deaths. 

Since their discovery, antibiotics have served as the cornerstone of modern medicine. However, extensive and widespread use of antimicrobial drugs has led to the emergence of resistant strains of microorganisms. These microorganisms are no longer susceptible to the currently available antimicrobial drugs. Today, bacteria are acquiring resistance to all available antibiotics at a much faster rate than the introduction of new drugs and are posing a serious and imminent threat to public health. Antimicrobial resistance has led to the emergence of untreatable superbugs that now threaten the basis of modern medicine. State-of-the-art approaches to treat these infections are desperately needed.

Antimicrobial peptides are part of the innate immune response found among all classes of life. Naturally occurring antimicrobial peptides efficiently and selectively kill bacteria by perturbing microbial membranes, facilitating the depletion of the microbial electrochemical potential. This leads to rapid membrane disruption and cell death, which is much faster than traditional antibiotics that target specific metabolic pathways. Some types of organisms, like insects, have evolved such peptides over millions of years to fights infections.

Omnix’s proprietary innovation allows these peptides to become druggable. Omnix has applied its platform technology predominantly to anticrobial peptides from the Cecropin peptide family. Using a breakthrough bioengineering strategy, the company has overcome the two main barriers that stand in the way of using antimicrobial peptides as effective therapeutic agents – stability and selectivity. By using a novel synthesis and biochemical engineering approaches, Omnix has produced highly potent peptides that are both selective and degradation resistant.

The company has based its design on insect host defense peptides due to their remarkable potency and pathogen-selective properties. The end results are novel, druggable and lifesaving pharmaceuticals.

Information sourced from https://omnixmedical.com/ verified solely by the company.